Top

Published in:

06-02-2024 | Pancreatic Cancer | Pancreatic Tumors

Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery

Authors: Shenghua Bi, MD, Yueping Jiang, MD, Ge Guan, MD, Xueguo Sun, MD, Xiaowei Wang, MD, Lingyun Zhang, MD, Xue Jing, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Background

Myosteatosis is correlated with poor prognosis in some malignancies. The creatinine-to-cystatin ratio (CCR) is revealed to predict gastric cancer prognosis. However, the prognostic abilities of CCR and the combination of CCR and myosteatosis in patients with pancreatic cancer (PC) who underwent radical surgery remains unclear.

Methods

The retrospective cohort study included 215 patients with PC who underwent radical surgery (January 2016–October 2021). Clinicopathological and serological data were collected on admission. Myosteatosis and other body composition indices were assessed by using computed tomography. The cutoff value of CCR was determined by using the Youden index. Risk factors responsible for poor overall survival (OS) and disease-free survival (DFS) were determined by the Cox proportional hazards model.

Results

The myosteatosis group included 104 patients (average age, 61.3 ± 9.1 years). The best cutoff value for CCR was 1.09. CCR ≤ 1.09 was an independent predictive biomarker inversely corelated with OS (P = 0.036). Myosteatosis was an independent risk factor associated with OS and DFS (P = 0.032 and P = 0.004, respectively). Patients with concomitant myosteatosis and CCR ≤ 1.09 had the worst OS (P = 0.016).

Conclusions

Myosteatosis and CCR are prognostic biomarkers for survival in PC patients who underwent radical surgery. Patients with the coexistence of myosteatosis and CCR ≤ 1.09 deserve more attention.

Available only for authorised users

Zhao T, Xiao D, Jin F, et al. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Br J Cancer. 2022;127(8):1461–72. https://doi.org/10.1038/s41416-022-01927-y.CrossRefPubMedPubMedCentral

Peng YC, Wu CH, Tien YW, Lu TP, Wang YH, Chen BB. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Eur Radiol. 2021;31(4):2472–81. https://doi.org/10.1007/s00330-020-07294-7.CrossRefPubMed

Schouten TJ, Daamen LA, Dorland G, et al. Nationwide validation of the 8th American joint committee on cancer TNM staging system and five proposed modifications for resected pancreatic cancer. Ann Surg Oncol. 2022;29(9):5988–99. https://doi.org/10.1245/s10434-022-11664-4.CrossRefPubMedPubMedCentral

Wang Z, Hu F, Chang R, et al. Development and validation of a prognostic model to predict overall survival for lung adenocarcinoma: a population-based study from the SEER database and the Chinese multicenter lung cancer database. Technol Cancer Res Treat. 2022;21:15330338221133222. https://doi.org/10.1177/15330338221133222.CrossRefPubMedPubMedCentral

Hopkins JJ, Reif RL, Bigam DL, Baracos VE, Eurich DT, Sawyer MB. The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer. Dis Colon Rectum. 2019;62(5):549–60. https://doi.org/10.1097/dcr.0000000000001352.CrossRefPubMed

Ishizu Y, Ishigami M, Honda T, et al. Factors associated with the progression of myosteatosis in patients with cirrhosis. Nutrition. 2022;103–4:111777. https://doi.org/10.1016/j.nut.2022.111777.CrossRef

Zhuang CL, Shen X, Huang YY, et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score-matched analysis from a large-scale cohort. Surgery. 2019;166(3):297–304. https://doi.org/10.1016/j.surg.2019.03.020.CrossRefPubMed

Srpcic M, Jordan T, Popuri K, Sok M. Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer. Radiol Oncol. 2020;54(2):237–46. https://doi.org/10.2478/raon-2020-0016.CrossRefPubMedPubMedCentral

Hong S, Kim KW, Park HJ, et al. Impact of baseline muscle mass and myosteatosis on the development of early toxicity during first-line chemotherapy in patients with initially metastatic pancreatic cancer. Front Oncol. 2022;12:878472. https://doi.org/10.3389/fonc.2022.878472.CrossRefPubMedPubMedCentral

10.

Tabara Y, Okada Y, Ochi M, Ohyagi Y, Igase M. Different associations of skeletal muscle mass index and creatinine-to-cystatin C ratio with muscle mass and myosteatosis: the J-SHIPP Study. J Am Med Direct Assoc. 2021;22(12):2600–2. https://doi.org/10.1016/j.jamda.2021.06.033.CrossRef

11.

Ulmann G, Kaï J, Durand JP, et al. Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: comparison to L3-computed tomography scan. Nutrition. 2021;81:110895. https://doi.org/10.1016/j.nut.2020.110895.CrossRefPubMed

12.

Gao J, Liang H, Qian Y, et al. Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer surgery. Ann Palliat Med. 2021;10(5):5017–26. https://doi.org/10.21037/apm-20-2366.CrossRefPubMed

13.

Shi S, Jiang Y, Chen W, Chen K, Liao Y, Huang K. Diagnostic and prognostic value of the creatinine/cystatin C ratio for low muscle mass evaluation among US adults. Front Nutr. 2022;9:897774. https://doi.org/10.3389/fnut.2022.897774.CrossRefPubMedPubMedCentral

14.

Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ. 2001;322(7281):276–8. https://doi.org/10.1136/bmj.322.7281.276.CrossRefPubMedPubMedCentral

15.

Bhanji RA, Takahashi N, Moynagh MR, et al. The evolution and impact of sarcopenia pre- and post-liver transplantation. Alimen Pharmacol Therap. 2019;49(6):807–13. https://doi.org/10.1111/apt.15161.CrossRef

16.

Pozzuto L, Silveira MN, Mendes MCS, et al. Myosteatosis differentially affects the prognosis of non-metastatic colon and rectal cancer patients: an exploratory study. Front Oncol. 2021;11:762444. https://doi.org/10.3389/fonc.2021.762444.CrossRefPubMedPubMedCentral

17.

Ebadi M, Tsien C, Bhanji RA, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions. Cells. 2022;11(7):1216. https://doi.org/10.3390/cells11071216.CrossRefPubMedPubMedCentral

18.

Reichelt S, Pratschke J, Engelmann C, Neumann UP, Lurje G, Czigany Z. Body composition and the skeletal muscle compartment in liver transplantation: turning challenges into opportunities. Am J Transpl. 2022;22(8):1943–57. https://doi.org/10.1111/ajt.17089.CrossRef

19.

Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018;12(4):377–86. https://doi.org/10.1007/s12072-018-9875-9.CrossRefPubMed

20.

Lascala F, da Silva Moraes BK, Mendes MCS, et al. Prognostic value of myosteatosis and systemic inflammation in patients with resectable gastric cancer: a retrospective study. Eur J Clin Nutr. 2022. https://doi.org/10.1038/s41430-022-01201-7.CrossRefPubMed

21.

Wang X, Sun M, Li Y, et al. Association of myosteatosis with various body composition abnormalities and longer length of hospitalization in patients with decompensated cirrhosis. Front Nutr. 2022;9:921181. https://doi.org/10.3389/fnut.2022.921181.CrossRefPubMedPubMedCentral

22.

Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. https://doi.org/10.1093/ageing/afz046.CrossRefPubMedPubMedCentral

23.

Chen WZ, Shen ZL, Zhang FM, et al. Prognostic value of myosteatosis and sarcopenia for elderly patients with colorectal cancer: a large-scale double-center study. Surgery. 2022;172(4):1185–93. https://doi.org/10.1016/j.surg.2022.05.031.CrossRefPubMed

24.

van Dijk DPJ, Zhao J, Kemter K, et al. Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. J Cach Sarcop Muscle. 2021;12(4):983–92. https://doi.org/10.1002/jcsm.12723.CrossRef

25.

Yamashita S, Iwahashi Y, Miyai H, et al. Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer. Sci Rep. 2020;10(1):22146. https://doi.org/10.1038/s41598-020-79340-9.CrossRefPubMedPubMedCentral

26.

Youn S, Eurich DT, McCall M, Walker J, Smylie M, Sawyer MB. Skeletal muscle is prognostic in resected stage III malignant melanoma. Clin Nutr. 2022;41(5):1066–72. https://doi.org/10.1016/j.clnu.2022.03.001.CrossRefPubMed

27.

Kim DW, Ahn H, Kim KW, et al. Prognostic value of sarcopenia and myosteatosis in patients with resectable pancreatic ductal adenocarcinoma. Korean J Radiol. 2022;23(11):1055–66. https://doi.org/10.3348/kjr.2022.0277.CrossRefPubMedPubMedCentral

28.

Meister FA, Lurje G, Verhoeven S, et al. The role of sarcopenia and myosteatosis in short- and long-term outcomes following curative-intent surgery for hepatocellular carcinoma in a european cohort. Cancers. 2022;14(3):720. https://doi.org/10.3390/cancers14030720.CrossRefPubMedPubMedCentral

29.

Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7(2):126–35. https://doi.org/10.1002/jcsm.12039.CrossRefPubMed

30.

Yi X, Fu Y, Long Q, et al. Myosteatosis can predict unfavorable outcomes in advanced hepatocellular carcinoma patients treated with hepatic artery infusion chemotherapy and anti-PD-1 immunotherapy. Front Oncol. 2022;12:892192. https://doi.org/10.3389/fonc.2022.892192.CrossRefPubMedPubMedCentral

31.

Czigany Z, Kramp W, Lurje I, et al. The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. J Cachexia Sarcopenia Muscle. 2021;12(2):358–67. https://doi.org/10.1002/jcsm.12669.CrossRefPubMedPubMedCentral

32.

Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;270(1):139–46. https://doi.org/10.1097/sla.0000000000002660.CrossRefPubMed

33.

O’Leary MF, Wallace GR, Davis ET, et al. Obese subcutaneous adipose tissue impairs human myogenesis, particularly in old skeletal muscle, via resistin-mediated activation of NFκB. Sci Rep. 2018;8(1):15360. https://doi.org/10.1038/s41598-018-33840-x.CrossRefPubMedPubMedCentral

34.

Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317(5839):807–10. https://doi.org/10.1126/science.1144090.CrossRefPubMed

35.

Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative visceral adiposity and muscularity predict poor outcomes after hepatectomy for hepatocellular carcinoma. Liver Cancer. 2019;8(2):92–109. https://doi.org/10.1159/000488779.CrossRefPubMed

36.

Zamboni M, Gattazzo S, Rossi AP. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur Geriatric Med. 2019;10(1):5–6. https://doi.org/10.1007/s41999-018-0134-3.CrossRef

37.

Rupert JE, Narasimhan A, Jengelley DHA, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218(6):e20190450. https://doi.org/10.1084/jem.20190450.CrossRefPubMedPubMedCentral

38.

Li Y, Wang WB, Yang L, et al. The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy. Nutrition. 2022;93:111464. https://doi.org/10.1016/j.nut.2021.111464.CrossRefPubMed

39.

Scopel Poltronieri T, de Paula NS, Chaves GV. Skeletal muscle radiodensity and cancer outcomes: a scoping review of the literature. Nutr Clin Pract. 2022;37(5):1117–41. https://doi.org/10.1002/ncp.10794.CrossRefPubMed

40.

Hamrick MW, McGee-Lawrence ME, Frechette DM. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity. Front Endocrinol. 2016;7:69. https://doi.org/10.3389/fendo.2016.00069.CrossRef

41.

Li CW, Yu K, Shyh-Chang N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022;13(2):781–94. https://doi.org/10.1002/jcsm.12901.CrossRefPubMedPubMedCentral

42.

Yokoyama N, Shirai Y, Wakai T, Nagakura S, Akazawa K, Hatakeyama K. Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma. World J Surg. 2005;29(4):519–23. https://doi.org/10.1007/s00268-004-7709-5.CrossRefPubMed

43.

Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365(6):565–7. https://doi.org/10.1056/NEJMcibr1106880.CrossRefPubMed

44.

van Abellan Kan G, Cameron Chumlea W, Gillette-Guyonet S, et al. Clinical trials on sarcopenia: methodological issues regarding phase 3 trials. Clin Geriatr Med. 2011;27(3):471–82. https://doi.org/10.1016/j.cger.2011.03.010.CrossRef

45.

Nachit M, De Rudder M, Thissen JP, et al. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle. 2021;12(1):144–58. https://doi.org/10.1002/jcsm.12646.CrossRefPubMed

46.

Mikami K, Endo T, Sawada N, et al. Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki health promotion project. J Clin Biochem Nutr. 2022;70(3):273–82. https://doi.org/10.3164/jcbn.21-61.CrossRefPubMed

47.

Tabara Y, Okada Y, Ochi M, Ohyagi Y, Igase M. Association of creatinine-to-cystatin C ratio with myosteatosis and physical performance in older adults: the Japan Shimanami health promoting program. J Am Med Direct Assoc. 2021;22(11):2366-72.e3. https://doi.org/10.1016/j.jamda.2021.03.021.CrossRef

48.

Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295–300. https://doi.org/10.1097/mnh.0000000000000115.CrossRefPubMed

49.

Li S, Lu J, Gu G, et al. Serum creatinine-to-cystatin C ratio in the progression monitoring of non-alcoholic fatty liver disease. Front Physiol. 2021;12:664100. https://doi.org/10.3389/fphys.2021.664100.CrossRefPubMedPubMedCentral

50.

Hyun YY, Lee KB, Kim H, et al. Serum creatinine to cystatin C ratio and clinical outcomes in adults with non-dialysis chronic kidney disease. Front Nutr. 2022;9:996674. https://doi.org/10.3389/fnut.2022.996674.CrossRefPubMedPubMedCentral

Title: Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery
Authors: Shenghua Bi, MD
Yueping Jiang, MD
Ge Guan, MD
Xueguo Sun, MD
Xiaowei Wang, MD
Lingyun Zhang, MD
Xue Jing, MD
Publication date: 06-02-2024
Publisher: Springer International Publishing
Keywords: Pancreatic Cancer
Pancreatic Cancer
Sarcopenia
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14969-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

ASO Author Reflections: Accuracy and Prognostic Impact of Nodal Status on Preoperative Imaging for Management of Pancreatic Neuroendocrine Tumors

Correction: Predictive Value of a New Muscle Parameter in Patients with Resectable Gastric Cancer: A Pooled Analysis of Three Prospective Trials

Neoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis

The Impact of Enhanced Recovery on Long-Term Survival in Rectal Cancer

ASO Visual Abstract: Gross Hematuria Does Not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma—A Multicenter Retrospective Cohort Study

ASO Author Reflections: Lymph Node Station 16 Status—Becoming a Student of Your Patients’ Cancer